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Abstract 
Almost 25 years since antiretroviral therapy (ART) was first shown to prevent mother-to-child 
transmission, 76% of pregnant women living with HIV receive ART annually, amounting to over 1 
million women). This reflects recent successes in universal ART scale-up in low and middle-income 
countries. Alongside unprecedented ART-related benefits to maternal and child health, challenges 
remain with regard to ART adherence, retention in care and uneven access to ART. Implementation 
research is ongoing to understand and address obstacles leading to loss-to-follow-up. Biological 
mechanisms underlying observed associations between antenatal ART and adverse pregnancy and 
birth outcomes are incompletely understood, with further research needed alongside strengthening 
of systems to assess safety of antiretroviral drugs for the mother and exposed child. In the treat all 
era, as duration on treatment and ART options expand, pregnant women will remain a priority 
population for treatment optimisation, to promote their health and that of their ART-exposed child.  
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Introduction 
Of 34.5 million adults living with HIV globally in 2016, 15.3 million (44%) were women of 
reproductive age; thus, nearly half of the population on or in need of antiretroviral therapy (ART) 
may become pregnant1. Provision of ART to women prior to and during pregnancy and breastfeeding 
prevents mother-to-child transmission (MTCT) and improves the health and survival of the mother2, 
which itself benefits the health of her children3. Treatment of pregnant women living with HIV is key 
to achievement of overall global health goals (including Sustainable Development Goal 3 and 
UNAIDS 90-90-90) as well as those relating specifically to maternal and child health, notably the 
UNAIDS Super Fast-Track Target of fewer than 20,000 new paediatric HIV infections by 2020.  
Pregnant women are considered a special population from a treatment perspective, largely due to 
the opportunity to prevent MTCT with antiretroviral drugs and the need to consider safety for the 
woman herself and the exposed foetus/child. Pregnancy was the first situation where “treatment as 
prevention” was applied programmatically, nearly 25 years ago, following the ACTG 076 randomised 
clinical trial (RCT) results in 19944. Thus, prior to the 2015 WHO “Treat All” recommendation, 
pregnancy has been a period where provision of ART to reduce MTCT has occurred in women not 
needing treatment for their own health. Pharmacokinetics (PK) is a further consideration: 
physiological changes in pregnancy (e.g. blood volume expansion; gastrointestinal, enzymatic and 
hormonal alterations) may alter PK properties of antiretroviral drugs, and can lead to altered 
absorption, reduced protein binding and increased elimination5. 
 
Preventing mother-to-child transmission of HIV-1 
Maternal HIV RNA load is the foremost risk factor for MTCT of HIV, and suppressive ART in 
pregnancy and breastfeeding thus the principal intervention to prevent transmission 6-8. Without any 
maternal ART 15-30% of formula-fed babies will become infected and up to 45% of those breastfed9. 
Rapid adoption of Zidovudine (ZDV) monotherapy (given antenatally, intrapartum and to the 
neonate) in high-income countries (HICs) after the ACTG 076 trial, which found a 68% reduced 
MTCT4, was followed by clinical trials in lower and middle income countries (LMICs), initially 
assessing abbreviated, simpler antiretroviral regimens and then combination ART prophylaxis10. 
Subsequent randomized and observational data showed that ZDV-monotherapy was inferior to ART 
in preventing MTCT11,12. WHO guidelines for treatment of HIV in pregnant women have evolved in 
the context of accumulating evidence of the effectiveness and safety of ART, changing drug 
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affordability and the need to simplify treatment programmes for programmatic scale-up2. Key 
milestones are presented in Figure 1.  
In HICs, implementation of ART has reduced MTCT rates to <1-2% since 200013,14 with extremely low 
rates being reported among women conceiving on ART, e.g. 0.2% in France in 2000-1015 and on a 
population level, e.g. 0.27% in the UK in 2012-201416. In LMICs, MTCT rates of <5% have been 
achieved in clinical trials11,12,17 and four Global Plan priority countries where women primarily 
breastfeed (South Africa, Uganda, Swaziland and Namibia; data up to 2016)9. Expanding coverage of 
ART in pregnancy in LMICs from 50% in 2010 to 75% in 2016 led to a 47% reduction in new paediatric 
HIV infections1.   
PMTCT services also play an important role in primary prevention for pregnant women who screen 
negative, particularly for those identified as being at high risk for HIV acquisition. For HIV-negative 
women in sero-discordant partnerships, the peri-conception period and pregnancy may be a time of 
heightened HIV acquisition risk due to reduced use of barrier protection and biological factors18, 
while risk of MTCT is elevated if incident maternal HIV infection does occur due to high HIV RNA load 
and lost opportunities for ARV prophylaxis19. Pre-exposure prophylaxis (PrEP)20 is one strategy of 
several that can be considered to support safer conception in serodiscordant couples, alongside a 
range of behavioural and biomedical interventions including fully suppressive treatment of 
partner(s) HIV infection21; current evidence, albeit limited, supports the safety of PrEP in the peri-
conception period and during pregnancy22,23. 
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ART coverage in pregnancy: temporal trends 
In HICs, where antenatal HIV prevalence is low compared with high prevalence LMIC settings, the 
vast majority of diagnosed pregnant women receive ART. This reflects high coverage of antenatal 
HIV screening alongside the increasing proportion of women already on ART at conception16,24. For 
example, in the UK and Ireland, 85% of pregnant women delivering in 2012-2014 were diagnosed 
before conception and 60% conceived on ART16.  Among the minority of women starting ART during 
pregnancy, ART is being started progressively earlier, for example, at a median of 22 weeks in a 
European pooled analysis of more than 7000 deliveries in 2008-1425.  
Around 90% of the annual 1.4 million pregnancies in HIV-positive women occur in sub-Saharan Africa 
(SSA), where ART scale-up among pregnant women was initially slow but with rapid acceleration in 
recent years (Figure 1). However, progress has been uneven, with coverage of 89% in Eastern and 
Southern Africa, 50% in West and Central Africa and 20% in North Africa and the Middle East1. The 
2015 WHO recommendation of lifelong ART for all those diagnosed with HIV, regardless of CD4 
count, had been adopted by 83% of LMICs and 94% of Fast Track countries by the end of 201726. This 
has resulted in a rapid rise of women on ART at conception in many LMICs, such as Botswana, where 
48% were on ART at conception in 2014 compared to only 19% in 200927. 
 
ART in pregnant women: challenges in uptake, adherence and engagement  
Experience in the Option B+ era has highlighted the multiple challenges in delivering and sustaining 
ART, on an individual and programmatic level, for women in pregnancy and postnatally24,28-36. 
Multiple individual, community, health system and other structural factors may positively or 
negatively influence access to HIV testing and treatment, adherence to ART and engagement in HIV 
care in pregnant women. Key barriers for initiation of and adherence to ART are outlined in Table 1, 
some of which are context-dependent and many of which are not unique to pregnancy. Of note, 
some barriers may result in delay in ART start rather than non-initiation, or gaps in treatment; these 
are of importance in the context of pregnancy where there is a limited time to achieve an 
undetectable HIV RNA level prior to delivery.  
Malawi was the innovator of the Option B+ approach in 2011 and thus the first country experiencing 
the related challenges of adherence and retention; a recent analysis showed that loss to follow-up 
(LTFU) was highest in the first year of ART, with 77% of women retained in care at 12 months after 
initiation, and that early signs of poor adherence were markers of subsequent LTFU33. A systematic 
review of studies investigating retention in care during pregnancy and the postnatal period in Africa 
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during the Option B+ era (with more than 60,000 women included), recently reported a pooled 
estimate of 6 month retention of 73% 37; of note, half of the studies were from Malawi and initiation 
of ART on the same day that HIV diagnosis took place was a risk factor for LTFU. 
Various delivery models for Option B+ have been assessed, alongside implementation research to 
understand and address obstacles leading to LTFU28,34; interventions include use of mentor mothers, 
lay counsellors, home visits, adherence groups, mobile health (mHealth) reminders, including SMS 
messages, and quality improvement strategies38. The MoMent Study in Nigeria showed significant 
benefits of a mentor mother intervention for retention in care (62% at six months post-partum 
versus 25% in controls) and viral load suppression (nearly five times more common at six months 
post-partum in women with mentor mother support)39. In Malawi, the PURE Study (a cluster RCT) 
showed that community- or facility-based expert peer support resulted in significantly greater 
retention in care at 24 months post-ART initiation40. In Mozambique, a stepped wedge cluster RCT 
evaluated workflow modifications and active patient tracking (including improved patient flow, 
continuous quality improvement, enhanced counselling and adherence committees) to promote 
Option B+ retention:  71% of women were retained for 30 day refills in the intervention period 
versus 52% in the control period, but by 90 days only around 40% of women were retained in both 
groups41.  
Adherence is also critical in pregnancy, as missed ART may lead to virological failure, increased risk 
of MTCT and potential transmission of drug resistant virus to the baby 42,43.  Programmatic changes 
to address adherence in pregnancy include a move to simplify ART with once-daily and fixed-dose 
combination regimens which has been associated with better adherence. However, studies from 
Europe have reported that 14-20% of pregnant women conceiving on ART have an unsuppressed 
viral load, with younger women, those with two or more children already and those diagnosed for 
longer periods at increased risk44,45. A recent study from rural South Africa reported that among 
pregnant women who had been on ART for ≥6 months prior to conception, 18% had detectable viral 
loads (>50 copies/ml) around this time46, with consistent findings from an earlier Cape Town study 
where 22% of women conceiving on ART had viral loads >50 copies/ml47. Even with multiple 
interventions ART adherence (≥90%, based on pharmacy refills) was only 23% for all women over a 
90 day period in the Mozambique cluster RCT referenced above41. These findings underscore the 
need for optimised regimens as well as appropriate interventions to maximize adherence before, 
during and after pregnancy as well as scale-up of viral load monitoring in pregnancy2.  
Issues around postnatal LTFU and ART adherence are also experienced in both low/middle income 
and resource-rich settings. In a systematic review and meta-analysis of >20,000 pregnant and 
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postnatal women with HIV from 51 studies, no difference in adherence levels according to setting 
(high versus low income) was found, with a pooled estimate of 74% of pregnant women having ART 
adherence above 80% (“adequate”)32. In a recent Swiss study, 34% of women did not return for an 
HIV care visit until 6-12 months after delivery and 12% were LTFU for >12 months48, whilst a single-
site study in the United States (US) reported only 39% of women being engaged in care one year 
post-delivery49. Disengagement from HIV care means interruption of ART, which has important 
implications for maternal health, for MTCT (for current and future infants) and horizontal 
transmission, while similar problems exist for those remaining in care postnatally but with 
deteriorating ART adherence; among 523 women starting ART during pregnancy in South Africa as 
Option B+ and achieving viral suppression during follow-up, there was an 11% increased incidence of 
subsequent viremia for each additional month postpartum50. 
 
Optimised regimens and newer antiretrovirals 
WHO guidelines currently recommend a fixed dose combination of Tenofovir disoproxil fumarate 
(TDF) with either Lamivudine (3TC) or Emtricitabine (FTC) plus the non-nucleoside reverse 
transcriptase inhibitor (NNRTI) Efavirenz (EFV) as first-line therapy2.  In 2016, new alternative options 
for ART for non-pregnant adults were included – with Dolutegravir (DTG), an integrase inhibitor, and 
EFV 400mg recommended for first line therapy and the Ritonavir (RTV, r) boosted protease inhibitor 
(PI) Darunavir (DRV/r) and Raltegravir (RAL), an integrase inhibitor, recommended for second or 
third line therapy, so called “optimised antiretroviral regimens”2. The rationale for this transition is 
to increase use of regimens that are highly effective, have low toxicity and high genetic barrier to 
resistance, few drug-drug interactions, taking into account key optimisation criteria including 
simplification, harmonization and cost, alongside safety considerations for special populations 
including pregnant women.  
WHO does not yet recommend DTG within preferred first-line regimens in pregnancy because of a 
lack of safety data and a recent concern about birth defects (see later section)51. While more than 20 
countries have updated their national guidelines to include DTG as a first-line option, with many 
adopting a phased transition, most are not recommending DTG for pregnant women or women 
planning to conceive.  The exception is Botswana, where DTG-based ART has been rolled-out to all 
HIV-infected adults including pregnant women. Nationwide implementation of TDF/FTC/DTG for all 
new initiations was completed rapidly over a few months 2016 and there are plans to transition 
older regimens to DTG pending further data on birth defects.   
8 
 
In HICs, recommended or preferred options (particularly for third agents) for initial regimens for 
ART-naïve pregnant women vary somewhat and guidelines are frequently updated. Currently,  the 
European AIDS Clinical Society (EACS) guidelines recommends RTV-boosted Atazanavir (ATV)/r as 
boosted PI, whilst the US and UK guidelines also recommend DRV/r. For integrase inhibitors, DTG is a 
recommended/preferred option in the UK and EACS guidelines, but remains an alternative option in 
the US52-54.  
Today, the majority of pregnant women in HICs are already on ART at conception; guidelines 
recommend review of their ART regimen, but it is generally recommended that a woman remains on 
her existing regimen if there are no tolerability issues and she has suppressed viral load52-54.  
Table 2 provides information on preclinical data, trans-placental passage, PK, clinical studies and the 
summary of product characteristics (SmPC) for four recently authorized antiretrovirals: Rilpivirine 
(RPV), a NNRTI authorized in 2011; Cobicistat (COBI, c), a booster authorized in 2013; DTG, 
authorized in 2014 and Tenofovir Alafenamide (TAF), a NRTI authorized in 2015. Of note, the SmPCs 
regarding pregnancy are mostly based on preclinical findings, with limited data on human 
pregnancy, mainly recommending avoiding use in pregnancy. However, real-world evidence shows 
significant increased use of these drugs over time, largely reflecting preconception initiation. For 
example, in the UK and Ireland National Study of HIV in Pregnancy and Childhood, exposure to any 
combination containing RPV or DTG increased more than 10-fold in 2013-2016 and 2015-2016 
respectively55. Increasing real-world use thus provides not only the rationale but also the means to 
address the gap between regulatory recommendations and real-world experience.  
Although dosing changes are rarely required for most currently recommended drugs, recent data on 
RPV has underscored the importance of PK studies in the context of pregnancy, with RPV area under 
the curve and trough concentration reduced in the second half of pregnancy compared with 
postpartum56; concerns regarding increased risk of virological failure has led to regulatory 
recommendations advising closer monitoring of viral load and/or to switch to another ART regimen 
in pregnancy.  
 
HIV treatment considerations in specific populations 
Late presenters 
For women not on ART at conception, prompt ART initiation is key to preventing MTCT as probability 
of transmission is strongly associated with duration of ART prior to delivery and particularly 
important for women with high baseline viral load52,54. To illustrate, in the French Perinatal Cohort, 
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the MTCT rate among women starting ART in the third trimester was 2.2% in 2000-2011, versus 0.7% 
in the entire cohort15. In HICs, a substantial proportion of women diagnosed with HIV antenatally are 
diagnosed late, for example, 32% in a European pooled analysis were diagnosed at 20 weeks 
gestation or later57, largely driven by late presentation. RAL is recommended in the scenario of late 
presentation to antenatal care and/or high viral loads in late pregnancy in a number of guidelines 
(within a three-drug regimen or with RAL intensification to an existing three-drug regimen) due to its 
transplacental transfer efficiency and rapid reduction in viral load52,54.  
In Thailand, RAL intensification for high risk pregnant women is now within national guidelines. A 
pilot study demonstrated the operational feasibility of adding RAL to standard ART in women 
presenting late (starting ART after 32 gestational weeks) or with viral load >1000 copies/ml at 34-38 
gestational weeks; viral load declined by a median 1.6 log10 copies/mL during a median 3 weeks 
intensification, with a 3.9% MTCT rate reported58. 
Once safety data on DTG accumulates, it is likely to replace RAL for late presenters as it should have 
similar efficacy but only needs to be taken once daily (RAL is twice daily). The DolPHIN-2 trial is 
investigating in Uganda and South Africa whether a DTG-based regimen is superior to EFV-based 
regimens in preventing MTCT for women initiating ART in the third trimester of pregnancy, with 
results expected in 2021.  
Hepatitis B virus co-infection 
Part of the WHO’s rationale for choosing XTC (3TC or FTC)+TDF as the NRTI backbone in first-line ART 
was its anti-HBV activity. In SSA, prevalence of HBV co-infection in pregnant women with HIV ranges 
from 2% to 16%, with up to 30% being HBeAg positive and thus at high risk of vertical HBV 
transmission59; meanwhile only around 40% of the world’s infants receive HBV vaccine at birth 60. 
Treating HIV/HBV co-infected pregnant women with a XTC+TDF-based regimen thus has potential to 
reduce vertical transmission of both infections, regardless of whether maternal HBV has been 
diagnosed 60. This public health aspect, alongside the HBV therapeutic benefit, requires 
consideration in future policy decisions regarding NRTI, including recycling in second-line therapies.  
Pregnant women who inject drugs 
There are an estimated 3.5 million WWID worldwide, with a higher HIV prevalence than seen among 
males who inject drugs61. WHO Guidelines present the key principles of HIV treatment and care for 
WWIDs, namely access to essential harm reduction (i.e. needle and syringe exchange programmes, 
opioid substitution therapy) and the same access to ART as other populations2. Pregnancy can be a 
strong motivator for reducing drug use, but discrimination, stigma, punitive drug policies and lack of 
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targeted/tailored services are major barriers to pregnant WWID accessing services61. Increased risk 
of non-receipt of antenatal ART has been described among WWID in an Eastern European setting62, 
whilst late presentation to antenatal care and high preterm delivery rates may contribute to shorter 
duration of antenatal ART in pregnant WWID accessing care. In terms of therapeutic management, 
interactions between methadone and some antiretrovirals (eg EFV, boosted PIs) may require 
methadone dose adjustment. 
 
Safety issues 
There remain some large gaps regarding the safe use of ART in pregnancy for newer antiretroviral 
drugs 27,63. A major factor has been the exclusion of pregnant women or women planning a 
pregnancy from registrational and strategic trials of ART (i.e. ineligibility for enrolment or exclusion 
of women who become pregnant). Furthermore, data relating to use in non-pregnant women is also 
limited, due to the predominance of male participants in clinical trials of new antiretroviral 
drugs/regimens, with only a quarter of patients in such trials being female64. For some recent trials, 
women becoming pregnant have been allowed to continue on study drug, with appropriate follow-
up of pregnancy and infant outcome65. Although this is a welcome trend, it remains the case that 
pregnancy-specific safety data can be very slow to accumulate for newer drugs, given the 
dependence on observational data (Table 2). 
Teratogenicity 
As increasing proportions of women are conceiving on ART, attention continues to be focused on the 
potential for human teratogenicity, particularly for newer drugs. Prior to 2018, studies of antenatal 
ART use demonstrated an overall similar prevalence of birth defects in ART-exposed infants 
compared with the general population, with no association between first trimester exposure to any 
ART and major birth defects66,67. To inform the development of the first harmonized WHO 
guidelines, and in response to case reports of neurological birth defects associated with EFV use, a 
series of systematic reviews were conducted. The most recent assessed first trimester exposure, 
finding no increased risk of birth defects in EFV-exposed infants 68. 
The Antiretroviral Pregnancy Registry (APR) collects prospective data where ART exposure is 
assessed prior to birth outcomes being reported, predominantly through voluntary reports from 
mainly US-based healthcare providers. The APR reports sufficient mother-infant pairs reported to 
rule out at least a 1.5-times increase in overall birth defects in infants exposed to ZDV, 3TC, TDF, 
abacavir, FTC, nevirapine, RTV, lopinavir (LPV) and ATZ, and a 2-times increase in those exposed to 
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DRV, RPV, EFV and RAL compared with the general US population69. Some studies have identified 
potential signals which require continued monitoring. For example, a US study reported a 
significantly increased risk of congenital abnormalities associated with ATZ exposure in the first 
trimester, and a relative increase in skin and musculoskeletal defects67, while the French Perinatal 
Cohort reported a two-fold increased risk of congenital heart defects associated with first trimester 
ZDV exposure 70 (although this was not found in the APR71).  
In May 2018, there were four reported cases of infants with neural tube defects (NTDs) among 426 
births to women who started DTG-based ART prior to conception in Botswana51, nearly 10 times 
higher than the expected prevalence of NTDs. These results are based on a small number of events 
and further data are needed to confirm or refute the findings, from the Tsepamo Study in Botswana 
and elsewhere. Other published studies of congenital defects in DTG-exposed pregnancies are 
limited at present. In the APR, among 133 live births reported (77 with first trimester exposure), 
3.0% had a birth defect72 (with 2.7% and 2.8% birth defect prevalence among infants with first and 
second/third trimester exposure respectively in the APR overall69). In the European Pregnancy and 
Paediatric HIV Cohort Collaboration, prevalence of birth defects was 4.9% (95% CI 1.4, 12.2%) among 
81 live births, of whom 42 had first trimester exposure73; national data from HIV-exposed 
pregnancies in the UK indicate a 2.9% birth defect rate74.   
One of the challenges of obtaining sufficient data on the risk of birth defects by ART regimen is that 
most of these exposures are occurring in LMIC where there has been a lack of systematic 
surveillance of drug safety in pregnancy.  In these settings, surveillance can be difficult because of 
lack of reliable medical and pharmacy records, home births and insufficient training to recognize 
birth defects.   However, recent efforts by several African countries to implement birth surveillance 
has shown early success and WHO is coordinating a system to pool this data to improve efficiency 
and reach27. 
Adverse birth outcomes 
Untreated HIV infection in pregnancy is associated with increased risk of a range of adverse birth 
outcomes including preterm delivery (PTD), low birthweight, small for gestational age (SGA) and 
stillbirth, with highest risk among women with advanced HIV disease/immunosuppression75. While 
ART reduces the risk of adverse birth outcomes associated with poor maternal health or infant HIV 
infection, combination ART can simultaneously increase the risk, particularly of PTD, via other 
incompletely understood mechanisms, with greater risk of adverse pregnancy outcome observed 
than with NRTI mono/dual therapy in both LMICs and HICs12,76. Proposed potential mechanisms 
include ART-induced disruption or reversal of the Th1 to Th2 shift that is a normal feature of 
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pregnancy, resulting in predisposition to early labour, and an increase in the inflammatory response 
following ART initiation as a result of immune reconstitution syndrome77. 
Combination ART was first associated with PTD in Europe in 1998, with subsequent studies showing 
presence/magnitude of association to differ by ART regimen, timing of initiation and setting. PIs 
(particularly when boosted with ritonavir) have been widely implicated in observational studies78-81 
and in the Mma Bana trial in Botswana which showed a PTD rate of 21.4% among women 
randomised to ZDV-3TC-LPV/r at 26-34 gestation weeks vs 11.8% among those randomised to ZDV-
3TC-ABC82. Progesterone levels may be reduced by PIs, resulting in growth restriction83 and providing 
a potential mechanistic link between PIs and increased PTD risk (spontaneous or iatrogenic), with 
progesterone supplementation for women on PIs being explored84. Data from the PROMOTE trial 
also show the impact of ART on estradiol levels, with LPV/r-based ART associated with an increase 
and EFV-based ART with a decrease in estradiol and correlations with SGA risk in both directions85.  
The PROMISE trial found an increased risk of very PTD <34 weeks and neonatal death <14 days in 
women randomised to LPV/r-TDF-FTC compared with LPV/r-ZDV-3TC, but not compared with ZDV 
monotherapy12, resulting in a focus on the safety of TDF-containing regimens. However, a recent 
meta-analysis of 17 studies found that TDF was associated with a reduced risk of PTD (RR 0.90, 
95%CI 0.81-0.99) and stillbirth (RR 0.60 95%CI 0.43-0.84) with increased risk of neonatal death <14 
days found only in the PROMISE study86. These results may indicate an issue with TDF-FTC used in 
combination with LPV/r, for example relating to the increased TDF levels seen when co-administered 
with LPV/r, or reflect a low rate of adverse outcomes in the ZDV-3TC arm of the PROMISE study 
rather than an elevated rate in the TDF-FTC arm2.  
National surveillance data on safety of TDF from Botswana are also reassuring, showing significantly 
reduced SGA among women initiating TDF/FTC/EFV in pregnancy and among women on 
TDF/FTC/EFV from conception compared to other ART regimens including ZDV/3TC/NVP and 
ZDV/3TC/LPV-r81,87. Women on TDF/FTC/EFV at conception also had a lower risk of SGA compared 
with women on TDF/FTC/NVP and TDF/FTC/LPV-r at conception, suggesting (like PROMISE) that it is 
difficult to isolate the fetal effect of individual antiretrovirals when used in combinations.  
Surveillance in Botswana also found a concerning risk for stillbirth among women on ZDV/3TC/NVP 
compared to other ART81.  Together, this underscores the need to evaluate the comparative safety 
of specific ART regimens in future research and surveillance.  
Uncertainties remain around the role of timing of ART initiation and adverse birth outcomes. Results 
from the UK/Ireland showed an association between LPV/r and PTD risk, but only if LPV/r was 
initiated before conception74. A meta-analysis of 19,189 mother-child pairs indicated a 20% 
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increased risk of PTD in pregnancies conceived on ART vs those with ART initiated during pregnancy, 
alongside a 53% increased risk of very PTD <34 weeks, and 30% increased risk of low birthweight88.  
Maternal disease stage is a key confounder of the association between timing of ART initiation and 
adverse outcomes, as illustrated in the UK/Ireland study where those conceiving on ART with a CD4 
>350 cells/mm3 had a lower unadjusted PTD rate (8.7%) than the groups initiating ART in pregnancy 
(11.3% if CD4 ≤350 cells/mm3, 10.7% if CD4 >350 cells/mm3)74. Interpretation of observational data 
on ART safety is complicated by the potential role of confounding by indication or channelling bias, 
changes over time in treatment guidelines and comparator groups, inaccuracies in ascertainment of 
gestational age in some studies (especially in settings without routine confirmation by ultrasound) 
and the fact that women starting ART later in pregnancy have less time on ART at risk of preterm 
delivery than those conceiving on treatment. In the “treat all” era, as more women conceive on ART 
with relatively high CD4 counts, safety data are needed that are relevant to the changing HIV-
positive pregnant population and to newer antiretroviral drugs, and that address limitations in the 
existing evidence base (for example around gestational age ascertainment). A more complete 
understanding of mechanistic links between antiretroviral drugs and adverse outcomes will, if found 
to be causal, provide the basis for development of interventions or risk-stratification strategies. 
 
Looking to the future 
The benefits of ART for prevention of MTCT and for maternal, child and public health are 
indisputable. Harmonized, universal regimens have been key to the magnitude of scale-up of ART in 
LMICs, with 76% of all pregnant women with HIV receiving ART in 2016 and declining MTCT rates 
documented worldwide. Every year, over a million pregnancies/foetuses are exposed to ART, 
underscoring safety implications on a population level, as even a very small increased risk of an 
adverse outcome may affect a large number of women and/or children. The unprecedented scale of 
exposure to antivirals in pregnancy has been a catalyst for pharmacovigilance strengthening in 
LMICs, although this remains work in progress27.  
More data are needed regarding the PK, safety and toxicity of newly authorized antiretroviral drugs, 
particularly given the increasing numbers of women of reproductive age requiring second-line 
regimens27,63. Safety data based on observational, real-world evidence is accumulating for new drugs  
whilst the VESTED trial (Table 2) will provide much needed randomised data comparing EFV/FTC/TDF 
with DTG/FTC plus either TAF or TDF in women starting ART in pregnancy.  
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New antiretroviral drugs may be licensed despite lack of data on key characteristics such as 
transplacental passage in human pregnancy, with SmPCs often recommending avoiding use in 
pregnancy (Table 2); however, the majority of women on ART are of reproductive age and at least 
half of pregnancies in HIV-positive women are likely to be unplanned89,90. This raises the question of 
whether more regulatory “push” is needed to ensure that pharmaceutical companies expedite the 
necessary studies to obtain pregnancy data, similar to the process for paediatric investigation plans. 
The potential safety signal with DTG at conception underscores the importance of large scale 
pharmacovigilance studies. Linked to this, clinical trials of new drugs, including long-acting 
injectables, should have provision to follow-up women becoming pregnant during the study, with 
consideration to remain on drug if appropriate. The Pregnancy and HIV/AIDS: Seeking Equitable 
Study (PHASES) initiative is an ongoing initiative to develop guidance for conducting ethical HIV 
research among pregnant women with the goal of providing accelerated access to treatment91. 
There are complex and incompletely understood relationships between antenatal ART and adverse 
pregnancy and birth outcomes as well as gaps in our understanding of any potential short to long-
term effects of intra-uterine and breastmilk exposure to antiretrovirals among HIV-exposed, 
uninfected (HEU) children. Evaluating the potential health risks of such exposures is challenging, but 
important as the numbers of HEU children will continue to increase27. Adverse health outcomes in 
HEU children reported to date include increased mortality, greater infectious disease morbidity, 
impaired growth, metabolic alterations, neurodevelopmental delays, altered immunity and 
mitochondrial abnormalities27,92,93. For all these areas, a better understanding is needed of potential 
causal pathways in order to explore whether any health risks can be mitigated. 
Treat all for life is a clear public health message, but not only demands adherence to ART and 
sustained engagement in HIV care on an individual level but also recognition of and interventions to 
overcome the structural barriers to effective long-term treatment. Pregnant women face specific 
challenges in this regard, particularly those newly diagnosed. Further implementation research is 
needed to ensure that the health of women living with HIV, and that of their families, is optimised. 
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Figure 1 Treatment of HIV: key milestones and global situation with a focus on pregnancy 
 
 
Numbers of adult women living with HIV and ART coverage of pregnant women are UNAIDS estimates1 
Footnote for Figure 1: 
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~ 90% of PLWH to be diagnosed, 90% of those to be accessing ART and 90% of those on ART to achieve 
undetectable VL by 2020; * eMTCT (elimination of MTCT): <50 cases of MTCT per 100,000 births and MTCT 
rate <5% in breastfeeding and <2% in non-breastfeeding populations) 
Option A: ZDV monotherapy and single-dose nevirapine; Option B: triple ART prophylaxis during pregnancy 
and breastfeeding period; Option B+: lifelong ART  
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Table 1: Barriers for initiation and adherence to ART in pregnancy 
  
Individual 
 
 
 
 Poor knowledge or misconceptions regarding HIV, VT or ART 
 Fears around side effects and potential harms of ART for themselves and 
their foetus / infant 
 Denial of HIV status 
 Depression and other mental health problems; emotional stress 
 Substance misuse 
 Conflicting priorities (e.g. child care, other care-taking responsibilities, 
employment) 
 Undisclosed HIV status and/or fear of disclosure 
 Costs and perceived costs (including transport to clinic) 
 Younger age 
 Low self-efficacy 
 Pregnancy-related nausea / sickness 
 Lack of or late presentation for antenatal care 
 Cultural beliefs (e.g. use of traditional medicines) 
Community / 
partner 
 
 Intimate partner violence 
 Stigma 
 Lack of support from partner, family, community 
Regimen 
 
 
 Regimen with poor tolerability  
 Complex regimen and scheduling requirements (pill burden, frequency) 
 Running out of pills 
Health 
system / 
delivery 
model 
 
 Under-resourced health system (staffing, drug availability, stock-outs, 
waiting times, delays in test results) 
 Centralised HIV services, poor coverage in rural / remote settings 
 Poor coverage and/or lack of integrated antenatal care / PMTCT services 
 Insufficient adherence support 
 Initiation of ART on same day as HIV diagnosis 
Other 
structural 
 Logistical challenges in accessing health services 
 
24,29-36  
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Table 2: Summary of pregnancy-related characteristics (preclinical, published product characteristics, pharmacokinetic, dosing and clinical studies) of 
newly authorized antiretrovirals  
Drug 
Preclinical safety data                                
(animal studies) 
Clinical data (pregnancy 
toxicity): statements 
from SmPC 
Transplacental 
passage 
PK / Dosing 
recommendations 
Ongoing clinical studies 
 
DTG 
Tivicay 
 
ABC/3TC/DTG 
Triumeq  
No developmental toxicity, 
teratogenicity. In studies in 
combo with 3TC increased 
in early embryonic deaths 
in rabbits at relatively low 
systemic exposures. DTG, 
3TC, ABC: no effect on M/F 
fertility. 
Limited data and effect 
on human pregnancy is 
unknown. Should be 
used only if the B> R to 
the foetus. 
 
See also 51 
High placental 
transfer 
(animal 
studies)◊ 
PK:  AUC may decrease in 
III- trim compared to PP, 
but good VL suppression in 
III-trim recipients.                                 
Dosing: No change 
indicated. 
 
 
 
 
DolPHIN1: safety+ PK study; 
IMPAACT P1026s: DTG PK 
pregnancy vs PP and infants; 
ING200336: ARIA sub-study for 
incident pregnancies: safety+ 
PK of Triumeq; 
DolPHIN-2: efficacy of DTG-
based vs EFV-based ART in 
women presenting late in  
pregnancy and their infants 
VESTED/ IMPAACT 2010 (see 
below) 
 
RPV 
Edurant  
 
FTC/TDF/RPV 
Eviplera  
 
FTC/TAF/RPV 
Odefsey  
No reproductive toxicity, 
no teratogenicity in rats 
and rabbits. No effect on 
fertility in animals, not 
known in humans. RPV 
liver toxicity associated 
with liver enzyme induction 
in rodents. 
Limited data. As a 
precautionary measure, 
preferable to avoid use 
in pregnancy. Odefsey: 
Effective contraceptives 
must be used; no 
adequate and well-
controlled studies in 
pregnant women. 
Moderate to 
high placental 
transfer 
(animal 
studies)◊ 
PK:  highly variable, AUC 
30% lower in pregnancy vs 
PP. Most pregnant women 
exceed target exposure, 
but those with detectable 
VL had lower RPV troughs. 
Dosing: RPV plasma 
concentration reduced but 
insufficient data to 
recommend dosing change. 
Study TMC114HIV3015 of 19 
pregnant women during II+III 
trim+ PP. Ten women 
completed the study with no 
MTCT, RPV was well tolerated 
during pregnancy and PP; 
IMPAACT P1026s: large PK 
pregnancy vs PP and their  
infants study including RPV  
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TAF 
Vemlidy 
 
FTC/TAF 
Descovy 
 
No reproductive toxicity 
(rats, rabbits), no effect on 
fertility, pregnancy or 
foetal parameters. Bone & 
kidney as main toxicity 
target with reduced 
mineral density (dogs, rats) 
No adequate and well 
controlled studies in 
pregnancy. Should be 
used only if B>R to the 
foetus. 
No data 
available on 
placental 
transfer◊ 
PK: No PK studies in human 
pregnancy. Dosing: 
Insufficient data to make 
dosing recommendation. 
VESTED / IMPAACT 2010: 
Safety + efficacy of 
DTG/FTC/TAF,  EFV/FTC/TDF,  
DTG/FTC/TDF in ART-naïve 
pregnant women and infant 
 
COBI 
Tybost 
 
FDCs:  
ATV/c, Evotaz 
DRV/c, Rezolsta 
EVG/c +FTC/TDF 
Stribild 
EVG/c +FTC/TAF 
Genvoya 
No Reproductive toxicity, 
no teratogenic effects 
(rats, rabbits), only in rats 
ossification changes (spinal 
column and sternebra) of 
foetuses at maternal toxic 
doses. Stribild: in rats 
increased post-
implantation loss and 
decreased foetal weights 
No or limited clinical 
data. Consider use only 
if B> R. ATV/c, DRV/c, 
FTC/TAF: No data in 
pregnant women. EVG/c 
FTC/TDF and EVG/c 
FTC/TAF: effective 
contraceptives should 
be used. 
Low placental 
transfer  
(animal 
studies)◊ 
PK: Exposure and boosting 
effect markedly reduced in 
pregnancy. 
Dosing: Not yet studied. 
When in combo with TDF, 
FTC no change in dose is 
indicated. 
IMPAACT P1026s: EVG/c, 
DRV/c, ATV/c,  PK pregnancy vs 
PP and their infants;  
PANNA: large PK study on ART 
including  EVG/c, DRV/c  
DTG= Dolutegravir; ABC: Abacavir; 3TC= Lamivudine; RPV= Rilpivirine; FTC=Emtricitabine; TDF=Tenofovir Disoproxil Fumarate; TAF= Tenofovir Alafenamide; 
COBI /c=Cobicistat; ATV= Atanazavir; DRV= Darunavir; EVG= Elvitegravir; combo= combination; M/F= male/female;  B>R= Benefit >Risk; PP= postpartum;; 
AUC= Area under the curve; VL= viral load; trim=trimester; SmPC: summary of product characteristics 
◊ Placental transfer categories- Mean or median cord blood/maternal delivery plasma drug ratio: High >0.6; Moderate 0.3-0.6; Low <0.3  
European Medicines Agency. Available from: http://www.ema.europa.eu/ema/ ; AIDS info, U.S. Department of Health and Human Services. Available from: 
https://aidsinfo.nih.gov/guidelines/htmltables/3/5947; i-base. Available from: http://i-base.info/htb/33406; NIH, U.S. Clinical Trials. Available at: 
https://clinicaltrials.gov/  
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Panel: search strategy 
 
We searched PubMed for publications using the following search terms: 
pregnan*, HIV, human immunodeficiency virus, antiretroviral, mother-
to-child transmission, vertical transmission, treat*, fet*, foet*, birth 
defect, preterm, adverse birth outcome, adherence, loss-to-follow-up, 
Option B+ and retention. We screened reference lists of identified 
studies and searched recent HIV conference abstracts and the grey 
literature including WHO and UNAIDS publications. 
 
We selected articles published in English from 1994 to 2017 judged to 
be most relevant, prioritising systematic reviews and meta-analyses as 
well as clinical trials, cohort/surveillance and PK studies pertinent to 
contemporary questions around use of ART in pregnancy. We focused 
on articles published in the last 10 years.  
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